Review



p stat1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc p stat1
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-Stat1+(Tyr701)+Rabbit+mAb/pmc13584615-100-51-52
    Average 94 stars, based on 16 article reviews
    p stat1 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer"

    Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer

    Journal: Cancer immunology research

    doi: 10.1158/2326-6066.CIR-26-0278

    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing STAT1 and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    Figure Legend Snippet: (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing STAT1 and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

    Techniques Used: Inhibition, Extraction, Flow Cytometry, Analysis, Quantitative Proteomics, Expressing, Western Blot, Marker, In Vitro

    Related Articles

    Membrane:

    Article Title: Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models
    Article Snippet: .. The membrane was blocked with TBST buffer (G2150, Servicebio Technology Co., Ltd. Wuhan, China) containing 5% bovine serum albumin and then incubated with primary antibody STAT1 (1:1,000, #9172T, Cell Signaling Technology, MA, USA), p-STAT1 (1:1,000, #7649T, Cell Signaling Technology, MA, USA), and β-actin (1:10,000, AC004, Abclonal, Wuhan, China) overnight at 4°C. .. Following this, the membranes were incubated with HRP-conjugated Goat anti-Rabbit IgG secondary antibody (1:8,000, AS014, ABclonal, Wuhan, China) at room temperature.

    Incubation:

    Article Title: Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models
    Article Snippet: .. The membrane was blocked with TBST buffer (G2150, Servicebio Technology Co., Ltd. Wuhan, China) containing 5% bovine serum albumin and then incubated with primary antibody STAT1 (1:1,000, #9172T, Cell Signaling Technology, MA, USA), p-STAT1 (1:1,000, #7649T, Cell Signaling Technology, MA, USA), and β-actin (1:10,000, AC004, Abclonal, Wuhan, China) overnight at 4°C. .. Following this, the membranes were incubated with HRP-conjugated Goat anti-Rabbit IgG secondary antibody (1:8,000, AS014, ABclonal, Wuhan, China) at room temperature.

    Article Title: Discovery of synthetic G-quadruplex DNA as SARS-CoV-2 helicase inhibitor with antiviral, anti-inflammatory and antioxidative properties
    Article Snippet: .. The membranes were blocked in blocking buffer (TBS [pH 7.6], 0.1% Tween-20, 5% nonfat dry milk) for at least 3 h at 4 °C and then incubated with the following primary antibody: p-JAK1 (Tyr1022/1023, #3331S, 1:1000), JAK1 (#3344 1:1000), p-JAK2 (Tyr1008‚ #8082S, 1:1000), JAK2 (#3230, 1:1000), p-TYK2 (Tyr1054/1055, #68790, 1:1000), TYK2 (#14193, 1:1000), p-STAT1 (Tyr701, #9171, 1:1000), STAT1 (#14994, 1:1000), p-STAT2 (Tyr690‚ #88410, 1:1000), STAT2 (#72604, 1:1000), p-STAT3 (Tyr705, #9145S, 1:500), STAT3 (#9139, 1:1000) and beta-actin (#3700, 1:2000) (all from CST, Frankfurt, Germany). .. HBE ALI lysates were analyzed with primary antibodies against GAPDH (#2118, 1:4000, CST), ISG15 (#sc-166755,1:200, Santa Cruz Biotechnology), Mx1 (#37849, 1:1000, CST), SARS-CoV-2 Nucleocapsid (#40143-R019, 1:10 000, Sino Biological), STAT1 (#9172, 1:1000, CST), phospho-STAT1 Y701 (#9171, 1:1000, CST).

    Cell-Signaling:

    Article Title: Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models
    Article Snippet: .. The membrane was blocked with TBST buffer (G2150, Servicebio Technology Co., Ltd. Wuhan, China) containing 5% bovine serum albumin and then incubated with primary antibody STAT1 (1:1,000, #9172T, Cell Signaling Technology, MA, USA), p-STAT1 (1:1,000, #7649T, Cell Signaling Technology, MA, USA), and β-actin (1:10,000, AC004, Abclonal, Wuhan, China) overnight at 4°C. .. Following this, the membranes were incubated with HRP-conjugated Goat anti-Rabbit IgG secondary antibody (1:8,000, AS014, ABclonal, Wuhan, China) at room temperature.

    Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer
    Article Snippet: Proteins were equally loaded, electrophoresed on SDS-PAGE gels and then transferred to a PVDF membrane (Millipore, IPVH00010). .. Blots were blocked with 5% non-fat dry milk (BioRad, 1706404) in PBS, then probed with the following antibodies in 5% BSA (Sigma-Aldrich, A7906) solution: MERTK (Cell Signaling Technology (CST), 38102), AXL (CST, 8661, RRID:AB_11217435), p44/42 (CST, 9102, RRID:AB_330744), p-p44/42 (CST, 9101, RRID:AB_331646), iNOS (CST, 13120, RRID:AB_2799268), PD-L1 (R&D Systems, AF1019, RRID:AB_354540), p-STAT1 (CST, 8062, RRID:AB_10949108), Arg1(CST, 93668, RRID:AB_2800207), and SOCS1 (CST, 55313). ..

    other:

    Article Title: Cardiomyocytes execute pro- and anti-inflammatory signaling of IFNγ-induced GBP5 by differential regulation of the inflammasome
    Article Snippet: The antibodies used for various experiments in this study are the following: Caspase 7, rabbit polyclonal (Cat. no. 9492, 1:1000; Cell Signaling Technology, Germany); GBP5, rabbit monoclonal (Cat. No. EPR28367, 1:1000; Abcam; Cambridge, United Kingdom); STAT1, rabbit polyclonal (Cat. No. 14994, 1:1000; Cell Signaling Technology, Germany); p-STAT1, rabbit polyclonal (Cat. No. 9167, 1:1000; Cell Signaling Technology, Germany); Vinculin, rabbit polyclonal (Cat. No. 4650, 1:1000; Cell Signaling Technology, Germany), OXPHOS cocktail (Cat. No. ab110413, Abcam).

    Blocking Assay:

    Article Title: Discovery of synthetic G-quadruplex DNA as SARS-CoV-2 helicase inhibitor with antiviral, anti-inflammatory and antioxidative properties
    Article Snippet: .. The membranes were blocked in blocking buffer (TBS [pH 7.6], 0.1% Tween-20, 5% nonfat dry milk) for at least 3 h at 4 °C and then incubated with the following primary antibody: p-JAK1 (Tyr1022/1023, #3331S, 1:1000), JAK1 (#3344 1:1000), p-JAK2 (Tyr1008‚ #8082S, 1:1000), JAK2 (#3230, 1:1000), p-TYK2 (Tyr1054/1055, #68790, 1:1000), TYK2 (#14193, 1:1000), p-STAT1 (Tyr701, #9171, 1:1000), STAT1 (#14994, 1:1000), p-STAT2 (Tyr690‚ #88410, 1:1000), STAT2 (#72604, 1:1000), p-STAT3 (Tyr705, #9145S, 1:500), STAT3 (#9139, 1:1000) and beta-actin (#3700, 1:2000) (all from CST, Frankfurt, Germany). .. HBE ALI lysates were analyzed with primary antibodies against GAPDH (#2118, 1:4000, CST), ISG15 (#sc-166755,1:200, Santa Cruz Biotechnology), Mx1 (#37849, 1:1000, CST), SARS-CoV-2 Nucleocapsid (#40143-R019, 1:10 000, Sino Biological), STAT1 (#9172, 1:1000, CST), phospho-STAT1 Y701 (#9171, 1:1000, CST).

    Transcranial Magnetic Stimulation:

    Article Title: Discovery of synthetic G-quadruplex DNA as SARS-CoV-2 helicase inhibitor with antiviral, anti-inflammatory and antioxidative properties
    Article Snippet: .. The membranes were blocked in blocking buffer (TBS [pH 7.6], 0.1% Tween-20, 5% nonfat dry milk) for at least 3 h at 4 °C and then incubated with the following primary antibody: p-JAK1 (Tyr1022/1023, #3331S, 1:1000), JAK1 (#3344 1:1000), p-JAK2 (Tyr1008‚ #8082S, 1:1000), JAK2 (#3230, 1:1000), p-TYK2 (Tyr1054/1055, #68790, 1:1000), TYK2 (#14193, 1:1000), p-STAT1 (Tyr701, #9171, 1:1000), STAT1 (#14994, 1:1000), p-STAT2 (Tyr690‚ #88410, 1:1000), STAT2 (#72604, 1:1000), p-STAT3 (Tyr705, #9145S, 1:500), STAT3 (#9139, 1:1000) and beta-actin (#3700, 1:2000) (all from CST, Frankfurt, Germany). .. HBE ALI lysates were analyzed with primary antibodies against GAPDH (#2118, 1:4000, CST), ISG15 (#sc-166755,1:200, Santa Cruz Biotechnology), Mx1 (#37849, 1:1000, CST), SARS-CoV-2 Nucleocapsid (#40143-R019, 1:10 000, Sino Biological), STAT1 (#9172, 1:1000, CST), phospho-STAT1 Y701 (#9171, 1:1000, CST).

    Immunohistochemistry:

    Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion
    Article Snippet: Stained slides were scanned using the Axio Scan Z1 digital slide scanner (Carl Zeiss) and analyzed using HALO 4.1 software (Indica Lab). .. The following antibodies were used for fluorescent IHC on mouse tissue: ERα (Abclonal, A12976, 1:500), PyV mT (Santa Cruz, 53481, 1:200), PanCK (Ventana, 760-2135, 1:10), α-SMA (DAKO, M0851, 1:400), CD31 (CST, 77699, 1:100), CD45 (CST, 70257, 1:200), Ly6G (CST, 87048, 1:100), NK1.1 (CST, 39197, 1:200), CD3 (Abcam, ab16669, 1:200), CD4 (CST 25229, 1:50), CD8 (CST, 98941, 1:200), F4/80 (CST, 70076, 1:200), CD206 (CST, 24595, 1:400), p-Stat1 (CST, 9167, 1:200), MHC II (BD, 107601, 1:200), Granzyme B (CST, 44153, 1:200), PD-1 (CST, 84651, 1:200), PD-L1 (CST, 64988, 1:100), Tim3 (CST, 83882, 1:200), CTLA4 (CST, 53560, 1:100), p-Stat5 (CST, 9314, 1:100), and p-Stat3 (CST, 9145, 1:100). .. The following antibodies were used for fluorescent IHC on human tissue: CD45 (Ventana, 760-4279, 1:10), PanCK (Ventana, 760-2135, 1:10), CD3 (Abcam, Ab16669, 1:200), CD68 (Ventana, 790-2931, 1:10), ERα (Ventana, 790-4324, 1:10), p-Stat5 (Abcam, ab32364, 1:50), and p-Stat3 (CST, 9145, 1:50).

    Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion.
    Article Snippet: Stained slides were scanned using the Axio Scan Z1 digital slide scanner (Carl Zeiss) and analyzed using HALO 4.1 software (Indica Lab). .. The following antibodies were used for fluorescent IHC on mouse tissue: ERα (Abclonal, A12976, 1:500), PyV mT (Santa Cruz, 53481, 1:200), PanCK (Ventana, 760-2135, 1:10), α-SMA (DAKO, M0851, 1:400), CD31 (CST, 77699, 1:100), CD45 (CST, 70257, 1:200), Ly6G (CST, 87048, 1:100), NK1.1 (CST, 39197, 1:200), CD3 (Abcam, ab16669, 1:200), CD4 (CST 25229, 1:50), CD8 (CST, 98941, 1:200), F4/80 (CST, 70076, 1:200), CD206 (CST, 24595, 1:400), p-Stat1 (CST, 9167, 1:200), MHC II (BD, 107601, 1:200), Granzyme B (CST, 44153, 1:200), PD-1 (CST, 84651, 1:200), PD-L1 (CST, 64988, 1:100), Tim3 (CST, 83882, 1:200), CTLA4 (CST, 53560, 1:100), p-Stat5 (CST, 9314, 1:100), and p-Stat3 (CST, 9145, 1:100). .. The following antibodies were used for fluorescent IHC on human tissue: CD45 (Ventana, 760-4279, 1:10), PanCK (Ventana, 760-2135, 1:10), CD3 (Abcam, Ab16669, 1:200), CD68 (Ventana, 790-2931, 1:10), ERα (Ventana, 790-4324, 1:10), p-Stat5 (Abcam, ab32364, 1:50), and p-Stat3 (CST, 9145, 1:50).

    Immunopeptidomics:

    Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion
    Article Snippet: Stained slides were scanned using the Axio Scan Z1 digital slide scanner (Carl Zeiss) and analyzed using HALO 4.1 software (Indica Lab). .. The following antibodies were used for fluorescent IHC on mouse tissue: ERα (Abclonal, A12976, 1:500), PyV mT (Santa Cruz, 53481, 1:200), PanCK (Ventana, 760-2135, 1:10), α-SMA (DAKO, M0851, 1:400), CD31 (CST, 77699, 1:100), CD45 (CST, 70257, 1:200), Ly6G (CST, 87048, 1:100), NK1.1 (CST, 39197, 1:200), CD3 (Abcam, ab16669, 1:200), CD4 (CST 25229, 1:50), CD8 (CST, 98941, 1:200), F4/80 (CST, 70076, 1:200), CD206 (CST, 24595, 1:400), p-Stat1 (CST, 9167, 1:200), MHC II (BD, 107601, 1:200), Granzyme B (CST, 44153, 1:200), PD-1 (CST, 84651, 1:200), PD-L1 (CST, 64988, 1:100), Tim3 (CST, 83882, 1:200), CTLA4 (CST, 53560, 1:100), p-Stat5 (CST, 9314, 1:100), and p-Stat3 (CST, 9145, 1:100). .. The following antibodies were used for fluorescent IHC on human tissue: CD45 (Ventana, 760-4279, 1:10), PanCK (Ventana, 760-2135, 1:10), CD3 (Abcam, Ab16669, 1:200), CD68 (Ventana, 790-2931, 1:10), ERα (Ventana, 790-4324, 1:10), p-Stat5 (Abcam, ab32364, 1:50), and p-Stat3 (CST, 9145, 1:50).

    Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion.
    Article Snippet: Stained slides were scanned using the Axio Scan Z1 digital slide scanner (Carl Zeiss) and analyzed using HALO 4.1 software (Indica Lab). .. The following antibodies were used for fluorescent IHC on mouse tissue: ERα (Abclonal, A12976, 1:500), PyV mT (Santa Cruz, 53481, 1:200), PanCK (Ventana, 760-2135, 1:10), α-SMA (DAKO, M0851, 1:400), CD31 (CST, 77699, 1:100), CD45 (CST, 70257, 1:200), Ly6G (CST, 87048, 1:100), NK1.1 (CST, 39197, 1:200), CD3 (Abcam, ab16669, 1:200), CD4 (CST 25229, 1:50), CD8 (CST, 98941, 1:200), F4/80 (CST, 70076, 1:200), CD206 (CST, 24595, 1:400), p-Stat1 (CST, 9167, 1:200), MHC II (BD, 107601, 1:200), Granzyme B (CST, 44153, 1:200), PD-1 (CST, 84651, 1:200), PD-L1 (CST, 64988, 1:100), Tim3 (CST, 83882, 1:200), CTLA4 (CST, 53560, 1:100), p-Stat5 (CST, 9314, 1:100), and p-Stat3 (CST, 9145, 1:100). .. The following antibodies were used for fluorescent IHC on human tissue: CD45 (Ventana, 760-4279, 1:10), PanCK (Ventana, 760-2135, 1:10), CD3 (Abcam, Ab16669, 1:200), CD68 (Ventana, 790-2931, 1:10), ERα (Ventana, 790-4324, 1:10), p-Stat5 (Abcam, ab32364, 1:50), and p-Stat3 (CST, 9145, 1:50).



    Similar Products

    94
    ABclonal Biotechnology anti p stat1 s727
    Anti P Stat1 S727, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-STAT1-S727+Rabbit+mAb/pmc13496150-137-28-33
    Average 94 stars, based on 1 article reviews
    anti p stat1 s727 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti p stat1 y701
    Anti P Stat1 Y701, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-STAT1-Y701+Rabbit+pAb/pmc13496150-137-22-27
    Average 94 stars, based on 1 article reviews
    anti p stat1 y701 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc p stat1
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-Stat1+(Tyr701)+Rabbit+mAb/pmc13584615-100-51-52
    Average 94 stars, based on 1 article reviews
    p stat1 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    ABclonal Biotechnology p stat1
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-STAT1-Y701+Rabbit+mAb/10__1016_slash_j__jgr__2026__101116-87-7-12
    Average 95 stars, based on 1 article reviews
    p stat1 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    96
    Proteintech anti p stat1
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    Anti P Stat1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/STAT1+Antibody/pm42000926-87-37-39
    Average 96 stars, based on 1 article reviews
    anti p stat1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    ABclonal Biotechnology anti p stat1 ap0054
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    Anti P Stat1 Ap0054, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/Phospho-STAT1-Y701+Rabbit+mAb/pm42425026-65-4-9
    Average 95 stars, based on 1 article reviews
    anti p stat1 ap0054 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    86
    Wuhan Sanying Biotechnology p stat1 rabbit polyclonal antibody
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1 Rabbit Polyclonal Antibody, supplied by Wuhan Sanying Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/antibody+p+polyclonal+rabbit+stat1/pm42112801-38-61-89
    Average 86 stars, based on 1 article reviews
    p stat1 rabbit polyclonal antibody - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology p stat1 antibody py701 4a
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1 Antibody Py701 4a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/p-Stat1+Antibody/pmc12968423-309-70-74
    Average 94 stars, based on 1 article reviews
    p stat1 antibody py701 4a - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    86
    Wanleibio p stat1
    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing <t>STAT1</t> and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    P Stat1, supplied by Wanleibio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/anti+stat1/pm42050662-93-33-35
    Average 86 stars, based on 1 article reviews
    p stat1 - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology pstat1 py701 4a
    Ruxolitinib blocks LPS and IFNγ-induced Janus kinase signaling. (A) Human macrophages were pre-treated with increasing concentrations of ruxolitinib for 15 min and subsequently stimulated with IFNγ (100 ng/ml) or LPS (100 ng/ml) for 3 h. Whole-cell lysate western blots showing effect of ruxolitinib on STAT1 and STAT2 phosphorylation by each stimulus. Blot is representative of two replicates from separate human donors. (B and C) Quantification of pSTAT2 and (C) <t>pSTAT1</t> band intensities in A. Source data are available for this figure: .
    Pstat1 Py701 4a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+stat1/p-Stat1+Antibody/pmc12915527-183-6-9
    Average 94 stars, based on 1 article reviews
    pstat1 py701 4a - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing STAT1 and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

    Journal: Cancer immunology research

    Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer

    doi: 10.1158/2326-6066.CIR-26-0278

    Figure Lengend Snippet: (A) Schematic of TAM extraction from murine TNBC tumors. (B) Flow cytometry analysis gating strategy comparing CXCL9 protein abundance captured in the media. (C) Flow cytometry analysis gating for CD11b+F4/80+ cells after culture. (D) Bar plots summarize flow cytometry across replicates for CXCL9 abundance in media (T-test, p < 0.001, n=3, SEM bars) (E) Bar plots summarize flow cytometry across replicates for CXCL9 and iNOS within TAMs. (One way ANOVA, p < 0.001 for all comparisons, n=6, SEM bars) (F) Schematic of TAM expression of markers after reprogramming. (G) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in 2153L TAMs. (H) Western blot analysis comparing STAT, MAPK, and TAM marker expression changes across in vitro treatments in T12 TAMs. (I) Dot plot for Day 7 scRNAseq dataset showing STAT1 and SOCS1 expression enriched in the CXCL9+ Mo.Mac population. Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

    Article Snippet: Blots were blocked with 5% non-fat dry milk (BioRad, 1706404) in PBS, then probed with the following antibodies in 5% BSA (Sigma-Aldrich, A7906) solution: MERTK (Cell Signaling Technology (CST), 38102), AXL (CST, 8661, RRID:AB_11217435), p44/42 (CST, 9102, RRID:AB_330744), p-p44/42 (CST, 9101, RRID:AB_331646), iNOS (CST, 13120, RRID:AB_2799268), PD-L1 (R&D Systems, AF1019, RRID:AB_354540), p-STAT1 (CST, 8062, RRID:AB_10949108), Arg1(CST, 93668, RRID:AB_2800207), and SOCS1 (CST, 55313).

    Techniques: Inhibition, Extraction, Flow Cytometry, Analysis, Quantitative Proteomics, Expressing, Western Blot, Marker, In Vitro

    Ruxolitinib blocks LPS and IFNγ-induced Janus kinase signaling. (A) Human macrophages were pre-treated with increasing concentrations of ruxolitinib for 15 min and subsequently stimulated with IFNγ (100 ng/ml) or LPS (100 ng/ml) for 3 h. Whole-cell lysate western blots showing effect of ruxolitinib on STAT1 and STAT2 phosphorylation by each stimulus. Blot is representative of two replicates from separate human donors. (B and C) Quantification of pSTAT2 and (C) pSTAT1 band intensities in A. Source data are available for this figure: .

    Journal: The Journal of Experimental Medicine

    Article Title: IFNγ-induced memory in human macrophages is sustained by the durability of cytokine signaling itself

    doi: 10.1084/jem.20250976

    Figure Lengend Snippet: Ruxolitinib blocks LPS and IFNγ-induced Janus kinase signaling. (A) Human macrophages were pre-treated with increasing concentrations of ruxolitinib for 15 min and subsequently stimulated with IFNγ (100 ng/ml) or LPS (100 ng/ml) for 3 h. Whole-cell lysate western blots showing effect of ruxolitinib on STAT1 and STAT2 phosphorylation by each stimulus. Blot is representative of two replicates from separate human donors. (B and C) Quantification of pSTAT2 and (C) pSTAT1 band intensities in A. Source data are available for this figure: .

    Article Snippet: The following primary antibodies were used: pSTAT1 pY701.4A (#136229; Santa Cruz Biotechnology, RRID:AB_2019074) diluted at 1:10,000, IRF1 D5E4 (#8478; Cell Signaling Technologies, RRID:AB_10949108) diluted at 1:1,000, β-tubulin TUB2.1 (T5201; Sigma-Aldrich, RRID:AB_609915) diluted at 1:10,000, and GAPDH H-12 (#166574; Santa Cruz Biotechnology, RRID:AB_2107296) diluted at 1:10,000.

    Techniques: Western Blot, Phospho-proteomics

    IFNγ induces long-lasting transcription factor activity and chromatin accessibility after washout. Macrophages were treated with LPS, IFNγ, and LPS in the presence of ruxolitinib for 8 h, as in . Cells were washed and cultured for an additional 88 h. ATACseq was performed after 8 h of stimulation and 4 days after washout. (A) Heatmap of Z-scored reads within ATAC peaks induced by either LPS or IFNγ (L2FC > 2, FDR < 0.01). Clusters were generated by unsupervised k-means clustering. Each column represents a biological replicate from the same human donor. (B) Top enriched motifs in clusters from A. (C) Boxplot quantifying log2 cpm of reads within IFNγ-induced ATAC peaks before and after cytokine washout. (D) Boxplot quantifying log2 cpm of reads within LPS-induced ATAC peaks before and after cytokine washout. (E) Boxplot quantifying log2 cpm of reads within ATAC peaks induced by both IFNγ and LPS (L2FC > 2, FDR < 0.01 for each) peaks before and after cytokine washout. (F) Barplot quantifying percent of transcription factor-bound motifs within STAT1 and IRF1 (IFNγ) and IRF1 and NF-κB (LPS) within induced ATAC peaks in C and D for unstimulated, IFNγ/LPS-stimulated macrophages, and stimulated macrophages 4 days after washout. Motif binding predicted using TOBIAS ATACseq footprinting analysis. Results are average of two technical replicates from a single subject; error bars display standard deviation. (G) Human macrophages were stimulated with IFNγ (100 ng/ml), LPS (100 ng/ml), or IFNβ (10 ng/ml) for 8 h, washed, and then cultured for an additional 66 h. Cells were collected, and whole cell western blotting for phosphorylated STAT1 was performed at the indicated time points. Blot is representative of three replicates from two separate human donors. All box/whisker plots indicate interquartile range and 1.5× interquartile range. Statistical tests were determined by paired Wilcoxon test. ****P < 0.0001. Source data are available for this figure: .

    Journal: The Journal of Experimental Medicine

    Article Title: IFNγ-induced memory in human macrophages is sustained by the durability of cytokine signaling itself

    doi: 10.1084/jem.20250976

    Figure Lengend Snippet: IFNγ induces long-lasting transcription factor activity and chromatin accessibility after washout. Macrophages were treated with LPS, IFNγ, and LPS in the presence of ruxolitinib for 8 h, as in . Cells were washed and cultured for an additional 88 h. ATACseq was performed after 8 h of stimulation and 4 days after washout. (A) Heatmap of Z-scored reads within ATAC peaks induced by either LPS or IFNγ (L2FC > 2, FDR < 0.01). Clusters were generated by unsupervised k-means clustering. Each column represents a biological replicate from the same human donor. (B) Top enriched motifs in clusters from A. (C) Boxplot quantifying log2 cpm of reads within IFNγ-induced ATAC peaks before and after cytokine washout. (D) Boxplot quantifying log2 cpm of reads within LPS-induced ATAC peaks before and after cytokine washout. (E) Boxplot quantifying log2 cpm of reads within ATAC peaks induced by both IFNγ and LPS (L2FC > 2, FDR < 0.01 for each) peaks before and after cytokine washout. (F) Barplot quantifying percent of transcription factor-bound motifs within STAT1 and IRF1 (IFNγ) and IRF1 and NF-κB (LPS) within induced ATAC peaks in C and D for unstimulated, IFNγ/LPS-stimulated macrophages, and stimulated macrophages 4 days after washout. Motif binding predicted using TOBIAS ATACseq footprinting analysis. Results are average of two technical replicates from a single subject; error bars display standard deviation. (G) Human macrophages were stimulated with IFNγ (100 ng/ml), LPS (100 ng/ml), or IFNβ (10 ng/ml) for 8 h, washed, and then cultured for an additional 66 h. Cells were collected, and whole cell western blotting for phosphorylated STAT1 was performed at the indicated time points. Blot is representative of three replicates from two separate human donors. All box/whisker plots indicate interquartile range and 1.5× interquartile range. Statistical tests were determined by paired Wilcoxon test. ****P < 0.0001. Source data are available for this figure: .

    Article Snippet: The following primary antibodies were used: pSTAT1 pY701.4A (#136229; Santa Cruz Biotechnology, RRID:AB_2019074) diluted at 1:10,000, IRF1 D5E4 (#8478; Cell Signaling Technologies, RRID:AB_10949108) diluted at 1:1,000, β-tubulin TUB2.1 (T5201; Sigma-Aldrich, RRID:AB_609915) diluted at 1:10,000, and GAPDH H-12 (#166574; Santa Cruz Biotechnology, RRID:AB_2107296) diluted at 1:10,000.

    Techniques: Activity Assay, Cell Culture, Generated, Binding Assay, Footprinting, Standard Deviation, Western Blot, Whisker Assay

    Cell surface–bound IFNγ mediates persistent signaling regardless of cytokine manufacturer and can be degraded by trypsinization. (A) Quantification of pSTAT1 intensity normalized to 3H IFNγ in . (B) Human macrophages were treated with Escherichia coli sourced IFNγ purchased from PeproTech and mammalian-sourced IFNγ purchased from Sigma-Aldrich and ACRO. Cells were treated at 100 ng/ml for 8 h, washed, and cultured for an additional 48 h in regular media prior to collection. Cells were collected for immunoblot at the indicated times. Representative blot of duplicates from one human subject. (C) Quantification of pSTAT1 band intensity normalized to tubulin at each time point in B. (D) Human A549 airway epithelial cells were stimulated with 100 ng/ml IFNγ, washed, and cultured for an additional 72 h. Cells were collected for immunoblot at the indicated timepoints. Representative blot of two replicates. (E) Quantification of pSTAT1 band intensity normalized to tubulin at each time point in D. (F) Human macrophages were treated with 100 ng/ml IFNγ for 8 h, washed, and lifted by scraping after incubation with either PBS, 0.5 mM EDTA in PBS, or trypsin. Cells were replated and cultured for an additional 24 h in regular media. Cells were collected for immunoblot at the indicated times. (G) Quantification of pSTAT1 band intensity normalized to GAPDH for each condition in F. Statistical tests were determined by single-tailed t test. *P < 0.05; **P < 0.01. Source data are available for this figure: .

    Journal: The Journal of Experimental Medicine

    Article Title: IFNγ-induced memory in human macrophages is sustained by the durability of cytokine signaling itself

    doi: 10.1084/jem.20250976

    Figure Lengend Snippet: Cell surface–bound IFNγ mediates persistent signaling regardless of cytokine manufacturer and can be degraded by trypsinization. (A) Quantification of pSTAT1 intensity normalized to 3H IFNγ in . (B) Human macrophages were treated with Escherichia coli sourced IFNγ purchased from PeproTech and mammalian-sourced IFNγ purchased from Sigma-Aldrich and ACRO. Cells were treated at 100 ng/ml for 8 h, washed, and cultured for an additional 48 h in regular media prior to collection. Cells were collected for immunoblot at the indicated times. Representative blot of duplicates from one human subject. (C) Quantification of pSTAT1 band intensity normalized to tubulin at each time point in B. (D) Human A549 airway epithelial cells were stimulated with 100 ng/ml IFNγ, washed, and cultured for an additional 72 h. Cells were collected for immunoblot at the indicated timepoints. Representative blot of two replicates. (E) Quantification of pSTAT1 band intensity normalized to tubulin at each time point in D. (F) Human macrophages were treated with 100 ng/ml IFNγ for 8 h, washed, and lifted by scraping after incubation with either PBS, 0.5 mM EDTA in PBS, or trypsin. Cells were replated and cultured for an additional 24 h in regular media. Cells were collected for immunoblot at the indicated times. (G) Quantification of pSTAT1 band intensity normalized to GAPDH for each condition in F. Statistical tests were determined by single-tailed t test. *P < 0.05; **P < 0.01. Source data are available for this figure: .

    Article Snippet: The following primary antibodies were used: pSTAT1 pY701.4A (#136229; Santa Cruz Biotechnology, RRID:AB_2019074) diluted at 1:10,000, IRF1 D5E4 (#8478; Cell Signaling Technologies, RRID:AB_10949108) diluted at 1:1,000, β-tubulin TUB2.1 (T5201; Sigma-Aldrich, RRID:AB_609915) diluted at 1:10,000, and GAPDH H-12 (#166574; Santa Cruz Biotechnology, RRID:AB_2107296) diluted at 1:10,000.

    Techniques: Cell Culture, Western Blot, Incubation

    Cell surface–bound IFNγ mediates persistent JAK/STAT signaling even after cytokine washout. (A) Human macrophages were stimulated with IFNγ (100 ng/ml) for 8 h, washed, and then cultured in regular media or media containing ruxolitinib (1 µM) or increasing concentrations of anti-IFNγ neutralizing antibody for an additional 28 h. Cells were collected, and whole cell western blotting for phosphorylated STAT1 and IRF1 was performed at indicated time points. Representative blot of duplicates from two separate subjects. (B) Human macrophages were stimulated with 100 ng/ml IFNγ for 3 h, washed, and then cultured in either ruxolitinib (1 µM), anti-IFNγ neutralizing antibody (10 µg/ml), or isotype control antibody (10 µg/ml) for 2 h. Samples were collected at the indicated times for immunoblot. Representative blot of duplicates from two separate subjects. (C) Quantification of pSTAT1 band intensities from B. (D) Human macrophages were stimulated with 100 ng/ml IFNγ for 8 h, washed, and cultured for an additional 88 h in regular media. Supernatants from stimulated macrophages were collected after the 8-h stimulation and 88 h after washout. This supernatant was used to stimulate fresh macrophages for 1 h in the presence/absence of ruxolitinib (1 µM) or anti-IFNγ neutralizing antibody (10 µg/ml). As a control, fresh macrophages were stimulated with media supplemented with 1 ng/ml IFNγ for 1 h. Representative blot of duplicates from two separate subjects. (E) Macrophages were left in regular media or pre-treated with 10 µg/ml CHX for 15 min and stimulated with 100 ng/ml IFNγ for 3 h. Treated macrophages were washed and subsequently cultured for 2 h in regular media, media supplemented with 10 µg/ml CHX, or anti-IFNγ neutralizing antibody (10 µg/ml) and collected for immunoblot. Duplicates from one subject are shown. (F) Quantification of pSTAT1 band intensities in E normalized to band intensity of macrophages treated with IFNγ for 3 h. (G) Human macrophages were stimulated with 100 ng/ml IFNγ for 8 h, washed, and cultured in regular media or media supplemented with 1 µM ruxolitinib for 16 h. After 16 h, cells were washed again and cultured in regular media for an additional 24 h. Cells were collected for immunoblot at indicated times. Representative blot of four replicates from two subjects. (H) Quantification of pSTAT1 band intensities in G normalized to band intensity of macrophages treated with IFNγ for 3 h. Statistical tests were determined by a single-tailed t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Source data are available for this figure: .

    Journal: The Journal of Experimental Medicine

    Article Title: IFNγ-induced memory in human macrophages is sustained by the durability of cytokine signaling itself

    doi: 10.1084/jem.20250976

    Figure Lengend Snippet: Cell surface–bound IFNγ mediates persistent JAK/STAT signaling even after cytokine washout. (A) Human macrophages were stimulated with IFNγ (100 ng/ml) for 8 h, washed, and then cultured in regular media or media containing ruxolitinib (1 µM) or increasing concentrations of anti-IFNγ neutralizing antibody for an additional 28 h. Cells were collected, and whole cell western blotting for phosphorylated STAT1 and IRF1 was performed at indicated time points. Representative blot of duplicates from two separate subjects. (B) Human macrophages were stimulated with 100 ng/ml IFNγ for 3 h, washed, and then cultured in either ruxolitinib (1 µM), anti-IFNγ neutralizing antibody (10 µg/ml), or isotype control antibody (10 µg/ml) for 2 h. Samples were collected at the indicated times for immunoblot. Representative blot of duplicates from two separate subjects. (C) Quantification of pSTAT1 band intensities from B. (D) Human macrophages were stimulated with 100 ng/ml IFNγ for 8 h, washed, and cultured for an additional 88 h in regular media. Supernatants from stimulated macrophages were collected after the 8-h stimulation and 88 h after washout. This supernatant was used to stimulate fresh macrophages for 1 h in the presence/absence of ruxolitinib (1 µM) or anti-IFNγ neutralizing antibody (10 µg/ml). As a control, fresh macrophages were stimulated with media supplemented with 1 ng/ml IFNγ for 1 h. Representative blot of duplicates from two separate subjects. (E) Macrophages were left in regular media or pre-treated with 10 µg/ml CHX for 15 min and stimulated with 100 ng/ml IFNγ for 3 h. Treated macrophages were washed and subsequently cultured for 2 h in regular media, media supplemented with 10 µg/ml CHX, or anti-IFNγ neutralizing antibody (10 µg/ml) and collected for immunoblot. Duplicates from one subject are shown. (F) Quantification of pSTAT1 band intensities in E normalized to band intensity of macrophages treated with IFNγ for 3 h. (G) Human macrophages were stimulated with 100 ng/ml IFNγ for 8 h, washed, and cultured in regular media or media supplemented with 1 µM ruxolitinib for 16 h. After 16 h, cells were washed again and cultured in regular media for an additional 24 h. Cells were collected for immunoblot at indicated times. Representative blot of four replicates from two subjects. (H) Quantification of pSTAT1 band intensities in G normalized to band intensity of macrophages treated with IFNγ for 3 h. Statistical tests were determined by a single-tailed t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Source data are available for this figure: .

    Article Snippet: The following primary antibodies were used: pSTAT1 pY701.4A (#136229; Santa Cruz Biotechnology, RRID:AB_2019074) diluted at 1:10,000, IRF1 D5E4 (#8478; Cell Signaling Technologies, RRID:AB_10949108) diluted at 1:1,000, β-tubulin TUB2.1 (T5201; Sigma-Aldrich, RRID:AB_609915) diluted at 1:10,000, and GAPDH H-12 (#166574; Santa Cruz Biotechnology, RRID:AB_2107296) diluted at 1:10,000.

    Techniques: Cell Culture, Western Blot, Control